Detalles de la búsqueda
1.
Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70 years and over.
Gynecol Oncol
; 187: 221-226, 2024 May 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-38821039
2.
Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer.
Br J Cancer
; 127(3): 569-576, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35440668
3.
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.
N Engl J Med
; 381(25): 2403-2415, 2019 12 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-31562800
4.
Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.
Gynecol Oncol
; 164(2): 245-253, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34906376
5.
ABBV-176, a PRLR antibody drug conjugate with a potent DNA-damaging PBD cytotoxin and enhanced activity with PARP inhibition.
BMC Cancer
; 21(1): 681, 2021 Jun 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34107902
6.
Synergistic therapeutic benefit by combining the antibody drug conjugate, depatux-m with temozolomide in pre-clinical models of glioblastoma with overexpression of EGFR.
J Neurooncol
; 152(2): 233-243, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33517558
7.
A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors.
Invest New Drugs
; 38(6): 1815-1825, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32524319
8.
A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR.
Invest New Drugs
; 38(5): 1483-1494, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32189093
9.
53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.
Gynecol Oncol
; 153(1): 127-134, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30686551
10.
Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma.
J Neurooncol
; 144(1): 205-210, 2019 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-31273577
11.
Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor.
Cancer
; 124(10): 2174-2183, 2018 05 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-29533458
12.
Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial.
Br J Cancer
; 118(8): 1042-1050, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29551775
13.
A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.
Invest New Drugs
; 36(5): 828-835, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29313279
14.
Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification.
BMC Cancer
; 16: 105, 2016 Feb 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-26879245
15.
A phase 1 study of ABT-806 in subjects with advanced solid tumors.
Invest New Drugs
; 33(3): 671-8, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-25895099
16.
Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies.
Invest New Drugs
; 33(4): 870-80, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-25933833
17.
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Non-Squamous EGFR-Wildtype NSCLC in the Phase 2 LUMINOSITY Trial.
J Clin Oncol
; : JCO2400720, 2024 Jun 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38843488
18.
Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma.
Cancer
; 119(2): 380-7, 2013 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-22833179
19.
CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study.
J Clin Oncol
; 41(1): 107-116, 2023 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35867965
20.
Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma.
Neurooncol Adv
; 5(1): vdac183, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36814898